1. Matei D, Filiaci V, Randall ME, et al. (2019): Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 380: 2317-2326.
2.
Sung H, Ferlay J, Siegel RL (2021): Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249.
3.
Abu-Rustum N, Yashar C, Arend R, et al. (2023): Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21: 181-209.
4.
Craft CS, Broekelmann TJ, Mecham RP (2018): Microfibril-associated glycoproteins MAGP-1 and MAGP-2 in disease. Matrix Biol 71-72: 100-111.
5.
Lemaire R, Bayle J, Mecham RP, et al. (2007): Microfibril-associated MAGP-2 stimulates elastic fiber assembly. J Biol Chem 282: 800-808.
6.
Combs MD, Knutsen RH, Broekelmann TJ, et al. (2013): Microfibril-associated glycoprotein 2 (MAGP2) loss of function has pleiotropic effects in vivo. J Biol Chem 288: 28869-28880.
7.
Albig AR, Becenti DJ, Roy TG, et al. (2008): Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvasc Res 76: 7-14.
8.
Kitahama S, Gibson MA, Hatzinikolas G, et al. (2000): Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells. Bone 27: 61-67.
9.
Walji TA, Turecamo SE, Sanchez AC, et al. (2016): Marrow adipose tissue expansion coincides with insulin resistance in MAGP1-deficient mice. Front Endocrinol (Lausanne) 7: 87.
10.
Craft CS, Pietka TA, Schappe T, et al. (2014): The extracellular matrix protein MAGP1 supports thermogenesis and protects against obesity and diabetes through regulation of TGF-β. Diabetes 63: 1920-1932.
11.
Craft CS, Zou W, Watkins M, et al. (2010): Microfibril- associated glycoprotein-1, an extracellular matrix regulator of bone remodeling. J Biol Chem 285: 23858-23867.
12.
Wang JK, Wang WJ, Cai HY, et al. (2018): MFAP2 promotes epithelial-mesenchymal transition in gastric cancer cells by activating TGF-β/SMAD2/3 signaling pathway. Onco Targets Ther 11: 4001-4017.
13.
Chen Z, Lv Y, Cao D, et al. (2020): Microfibril-associated protein 2 (MFAP2) potentiates invasion and migration of melanoma by EMT and Wnt/β-catenin pathway. Med Sci Monit 26: e923808.
14.
Sun T, Wang D, Ping Y, et al. (2020): Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients. Int J Oncol 56: 460-469.
15.
Kujawa KA, Zembala-Nożynska E, Syrkis JP, et al. (2022): Microfibril associated protein 5 (MFAP5) is related to survival of ovarian cancer patients but not useful as a prognostic biomarker. Int J Mol Sci 23: 15994.
16.
Wei R, Song J, Liu X, et al. (2024): Immunosuppressive MFAP2(+) cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer. Cell Oncol (Dordr) 47: 55-68.
17.
Mecham RP, Gibson MA (2015): The microfibril-associated glycoproteins (MAGPs) and the microfibrillar niche. Matrix Biol 47: 13-33.
18.
Zhao LQ, Sun W, Zhang P, et al. (2022): MFAP2 aggravates tumor progression through activating FOXM1/β-catenin-mediated glycolysis in ovarian cancer. Kaohsiung J Med Sci 38: 772-780.
19.
Meier-Abt F, Milani E, Roloff T, et al. (2013): Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Res 15: R36.
20.
Freihen V, Rönsch K, Mastroianni J, et al. (2020): SNAIL1 employs β-Catenin-LEF1 complexes to control colorectal cancer cell invasion and proliferation. Int J Cancer 146: 2229-2242.
21.
Zhu Y, Wang W, Wang X (2015): Roles of transcriptional factor 7 in production of inflammatory factors for lung diseases. J Transl Med 13: 273.
22.
Saegusa M, Hashimura M, Kuwata T, et al. (2005): Upregulation of TCF4 expression as a transcriptional target of beta-catenin/p300 complexes during trans-differentiation of endometrial carcinoma cells. Lab Invest 85: 768-779.
23.
Conza D, Mirra P, Calì G, et al. (2021): Metformin dysregulates the unfolded protein response and the WNT/β-catenin pathway in endometrial cancer cells through an AMPK-independent mechanism. Cells 10: 1067.
24.
Gong J, Wang ZX, Liu ZY (2017): miRNA 1271 inhibits cell proliferation in neuroglioma by targeting fibronectin 1. Mol Med Rep 16: 143-150.
25.
Dang E, Yang S, Song C, et al. (2018): BAP31, a newly defined cancer/testis antigen, regulates proliferation, migration, and invasion to promote cervical cancer progression. Cell Death Dis 9: 791.
26.
Kim J, Jung KH, Yan HH, et al. (2018): Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma. BMC Complement Altern Med; 18: 147.
27.
Tang Z, Kang B, Li C, et al. (2019): GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 47: W556-w560.
28.
Yu G, Wang LG, Han Y, et al. (2012): clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16: 284-287.
29.
Love MI, Huber W, Anders S (2014): Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550.
30.
Yoshihara K, Shahmoradgoli M, Martínez E, et al. (2013): Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4: 2612.
31.
Bindea G, Mlecnik B, Tosolini M, et al. (2013): Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39: 782-795.
32.
Ru B, Wong CN, Tong Y, et al. (2019): TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 35: 4200-4202.
33.
Santiago L, Daniels G, Wang D, et al. (2017): Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res 7: 1389-1406.
34.
Williams ED, Gao D, Redfern A, et al. (2019): Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nat Rev Cancer 19: 716-732.
35.
Yao LW, Wu LL, Zhang LH, et al. (2020): MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway. Oncogenesis 9: 17.
36.
Gong X, Dong T, Niu M, et al. (2020): lncRNA LCPAT1 upregulation promotes breast cancer progression via enhancing MFAP2 transcription. Mol Ther Nucleic Acids 21: 804-813.
37.
Nguyen VHL, Hough R, Bernaudo S, et al. (2019): Wnt/β-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis. J Ovarian Res 12: 122.
38.
Nusse R, Clevers H (2017): Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169: 985-999.
39.
Zhang LN, Huang YH, Zhao L (2019): Fusion of macrophages promotes breast cancer cell proliferation, migration and invasion through activating epithelial-mesenchymal transition and Wnt/-catenin signaling pathway. Arch Biochem Biophys 676: 108137.
40.
Sierra RA, Hoverter NP, Ramirez RN, et al. (2018): TCF7L1 suppresses primitive streak gene expression to support human embryonic stem cell pluripotency. Development 145: 161075.
41.
Gaston-Massuet C, McCabe MJ, Scagliotti V, et al. (2016): Transcription factor 7-like 1 is involved in hypothalamo-pituitary axis development in mice and humans. Proc Natl Acad Sci U S A; 113: E548-557.
42.
Liang R, Liu Y (2018): Tcf7l1 directly regulates cardiomyocyte differentiation in embryonic stem cells. Stem Cell Res Ther 9: 267.
43.
Shan J, Shen J, Wu M, et al. (2019): Tcf7l1 acts as a suppressor for the self-renewal of liver cancer stem cells and is regulated by IGF/MEK/ERK signaling independent of β-catenin. Stem Cells 37: 1389-1400.
44.
Ku AT, Shaver TM, Rao AS, et al. (2017): TCF7L1 promotes skin tumorigenesis independently of β-catenin through induction of LCN2. Elife 6: e23242.
45.
Zhang B, Wu J, Cai Y, et al. (2019): TCF7L1 indicates prognosis and promotes proliferation through activation of Keap1/NRF2 in gastric cancer. Acta Biochim Biophys Sin (Shanghai) 51: 375-385.
46.
Oliveira G, Wu CJ (2023): Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer 23: 295-316.
47.
Bruni D, Angell HK, Galon J (2020): The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 20: 662-680.
48.
Roelands J, Kuppen PJK, Ahmed EI, et al. (2023): An integrated tumor, immune and microbiome atlas of colon cancer. Nat Med 29: 1273-1286.
49.
Pagès F, Mlecnik B, Marliot F, et al. (2018): International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391: 2128-2139.
